Improving of Cognition and Quality of Life in Schizophrenia With One-month and Three-month Paliperidone Palmitate Treatment

Abstract An antipsychotic drug, Paliperidone palmitate (PDP), is administered to schizophrenics as injections at one-month (Sustenna) or three-month (Trinza) intervals. The present study was a series of clinical trial study, which included two sub-study, sought to compare the effects of treatment, social function, and side effects between two treatments in schizophrenics. In Study 1, total of 42 participants were received the Sustenna treatment for three months. In Study 2, total of 72 participants were recruited for Trinza treatment. The results showed Personal and Social Performance scales (PSP) significantly increased over time with both two treatments. Total cholesterol levels significantly decreased with Sustenna, which negatively influenced the cognitive functions, and the quality of life. UKU scales significantly decreased with Trinza after 15 months. In Brief, schizophrenics receiving PDP treatment presented improvements in their cognitive and social functions over the time, whether with the Sustenna or Trinza treatment. Total cholesterol and waist circumference decreased, and the LDL/HDL ratios increased over the time after PDP treatment. Furthermore, patients receiving Trinza treatment experienced decreased side effects. Nonetheless, schizophrenics had a significantly better quality of life after both Sustenna and Trinza treatment. Future studies should be consider larger samples and longer follow up.